{"id":"NCT00660192","sponsor":"Yale University","briefTitle":"Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches","officialTitle":"Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-01","primaryCompletion":"2012-07","completion":"2015-07","firstPosted":"2008-04-17","resultsPosted":"2016-03-14","lastUpdate":"2016-03-14"},"enrollment":25,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Refractory Migraine"],"interventions":[{"type":"DRUG","name":"Botox","otherNames":["onobotulinumtoxinA"]},{"type":"OTHER","name":"Placebo","otherNames":["Saline"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Botox","type":"ACTIVE_COMPARATOR"}],"summary":"The hypothesis of this study is that injection of botulinum toxin A into the muscles around the head (frontal, temporal, posterior neck, occipital) can reduce the intensity and frequency of migraine headaches by 50%.","primaryOutcome":{"measure":"Mean Number of Days of Decrease in Pain Level Using VAS","timeFrame":"4 weeks","effectByArm":[{"arm":"Placebo","deltaMin":1.2,"sd":5.63},{"arm":"Botullinum Toxin","deltaMin":8.67,"sd":8.18}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0347"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Pain at injection site","Cold symptoms"]}}